Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.49 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | IARS1 | P41252 | 1/20 | 0.30 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.30 |
| ▸ | MARS1 | P56192 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24917230 | 0.91 | TMPRSS2 (0.50) | TMPRSS2EGLN2NR4A1 | |
| SCHEMBL24916850 | 0.90 | TMPRSS2 (0.52) | TMPRSS2SMN1; SMN2 | |
| SCHEMBL24917254 | 0.89 | TMPRSS2 (0.49) | TMPRSS2EGLN2 | |
| SCHEMBL24917188 | 0.89 | TMPRSS2 (0.54) | TMPRSS2SMN1; SMN2 | |
| SCHEMBL25917380 | 0.89 | TMPRSS2 (0.50) | TMPRSS2IARS1MARS1 | |
| SCHEMBL30472930 | 0.89 | TMPRSS2 (0.50) | TMPRSS2IARS1MARS1 | |
| SCHEMBL24789427 | 0.89 | TMPRSS2 (0.50) | TMPRSS2IARS1MARS1 | |
| SCHEMBL24917594 | 0.88 | TMPRSS2 (0.61) | TMPRSS2EGLN2SMN1; SMN2 | |
| SCHEMBL30973715 | 0.87 | TMPRSS2 (0.49) | TMPRSS2EGLN2IARS1MARS1 | |
| SCHEMBL24789733 | 0.87 | TMPRSS2 (0.60) | TMPRSS2EGLN2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638715-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885EGLN2 2347/4885SMN1; SMN2 862/4885 |
| US-20230233593-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | SLC29A2, SLC29A1, PNP | TMPRSS2 100/4885EGLN2 2347/4885SMN1; SMN2 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.